Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22480279 | 0.93 | LPAR1 (0.87) | LPAR1SLCO1B1SLC6A9ALDH1A1 | |
| SCHEMBL22480425 | 0.92 | LPAR1 (0.86) | LPAR1SLCO1B1FFAR4SLC6A9 | |
| SCHEMBL22480303 | 0.91 | LPAR1 (0.84) | LPAR1SLCO1B1SLC6A9 | |
| SCHEMBL22480563 | 0.89 | LPAR1 (0.80) | LPAR1SLCO1B1ALOX5ALOX5APSLC6A9 | |
| SCHEMBL22480277 | 0.87 | LPAR1 (0.82) | LPAR1SLCO1B1ALOX5ALOX5APSLC6A9 | |
| SCHEMBL22480374 | 0.86 | LPAR1 (0.76) | LPAR1SLCO1B1FFAR4SLC6A9 | |
| SCHEMBL22480362 | 0.86 | LPAR1 (0.75) | LPAR1SLCO1B1SLC6A9 | |
| SCHEMBL22480300 | 0.86 | LPAR1 (0.75) | LPAR1SLCO1B1SLC6A9 | |
| SCHEMBL22480292 | 0.86 | LPAR1 (0.75) | LPAR1SLCO1B1SLC6A9 | |
| SCHEMBL22480428 | 0.85 | LPAR1 (0.74) | LPAR1SLCO1B1FFAR4SLC6A9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728210-B1 | ISOXAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | claimed |
| EP-3728210-B1 | ISOXAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20200308157-A1 | ISOXAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308157-A1 | ISOXAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885SLCO1B1 1123/4885ALOX5 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.